8-KLeadership ChangesShareholder MattersExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (May 12, 2020)

Filed May 12, 2020For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K report detailing the outcomes of its Annual Stockholder Meeting held on May 7, 2020. The most significant outcome for investors is the stockholder approval of the amended and restated 2011 Long-Term Incentive Plan, which will become effective on October 1, 2020. This plan is crucial for attracting, retaining, and motivating key employees and executives, directly impacting the company's ability to execute its long-term strategy and drive shareholder value. Additionally, the meeting saw the overwhelming election of all ten director nominees, indicating strong shareholder confidence in the current board's leadership. Shareholders also approved the advisory vote on executive compensation, signaling support for the company's pay practices. The ratification of Ernst & Young LLP as the independent auditor further solidifies financial reporting integrity. Notably, a proposal requesting a report on non-management employee representation on the Board of Directors was not approved.

Key Highlights

  • 1Stockholders approved the amendment and restatement of the 2011 Long-Term Incentive Plan, effective October 1, 2020.
  • 2All ten director nominees were overwhelmingly elected to the Board of Directors.
  • 3The advisory vote on the compensation for Named Executive Officers was approved.
  • 4Ernst & Young LLP was ratified as the company's independent registered public accounting firm for fiscal year 2020.
  • 5A stockholder proposal requesting a report on non-management employee representation on the Board of Directors was not approved.
  • 6The Annual Meeting was held in a virtual-only format via live audio webcast.

Frequently Asked Questions

The Amended 2011 Long-Term Incentive Plan, approved by stockholders and effective October 1, 2020, is designed to provide incentives to key employees and executives. This plan is crucial for attracting, retaining, and motivating talent, which is essential for the company's long-term performance and success in achieving its strategic objectives and creating shareholder value.

The advisory vote on the compensation for Boston Scientific's Named Executive Officers was approved by stockholders. This indicates that shareholders are generally satisfied with the company's executive compensation practices as disclosed in the proxy statement.

Yes, a stockholder proposal requesting a report on the inclusion of non-management employee representation on the Board of Directors was not approved. This suggests that the majority of shareholders did not support this specific initiative at this time.

The appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the 2020 fiscal year was ratified by the stockholders.